Sridhar Venkatesh moved from Singapore to take over the top job as managing director at GlaxoSmithKline Pharmaceuticals Ltd. in India bang in the middle of the pandemic in 2020.
GSK India Chief On Pandemic Decisions, Refreshing The Portfolio
GSK India managing director Sridhar Venkatesh outlines how the company navigated pandemic-related turbulence and “stuck its neck out” to ensure uninterrupted supplies of key drugs. The executive also discusses launch prospects for products including Xevudy in India and an intent to “refresh” the company’s vaccines portfolio.
More from Business
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
More from Scrip
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.